Cartesian Therapeutics, Inc. ·
RNAC 8-K 2026-09-29
Cartesian Therapeutics, Inc. (RNAC) 8-K dated 2026-09-29 — accession 0001453687-26-000105.
Cartesian Therapeutics, Inc. (RNAC) is a biotechnology company listed on US.
Cartesian Therapeutics, Inc. filed a 8-K on 2026-09-29. Accession 0001453687-26-000105.
This 8-K covers: Reg FD disclosure (Item 7.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported RNAC revenue for 2025-12-31 was $2.8M. Net income was -$130.3M. Revenue was down 92.8% from 2024-12-31 to 2025-12-31. RNAC currently screens at market cap $290.9M.
Not investment advice. The RNAC SEC hub lists recent forms. The stock page is the research view.